Ed Belongia MD
@belongia.bsky.social
Vaccines & viruses | Epidemiology & public health | Former CDC & ACIP | Climate advocate | Dog walker & e-biker
Google Scholar: https://scholar.google.com/citations?user=X2F2it0AAAAJ&hl=en
Google Scholar: https://scholar.google.com/citations?user=X2F2it0AAAAJ&hl=en
Reposted by Ed Belongia MD
gift link: www.nytimes.com/2025/10/27/h...
October 27, 2025 at 11:29 PM
gift link: www.nytimes.com/2025/10/27/h...
New Zealand is incredible! The Wanaka Tree is one of my favorite shots.
October 19, 2025 at 11:41 PM
New Zealand is incredible! The Wanaka Tree is one of my favorite shots.
Now that’s a novel idea.
October 12, 2025 at 12:28 AM
Now that’s a novel idea.
And they ignored the pandemic response plan that was developed during the Obama administration.
October 11, 2025 at 3:03 PM
And they ignored the pandemic response plan that was developed during the Obama administration.
The license remains valid even if the product is not sold in the US. For example, the live shingles vaccine (Zostavax) is still licensed but Merck does not sell it in the US. The left the US market after ACIP made a preferential recommendation for the recombinant shingles vaccine (Shingrix).
October 10, 2025 at 1:38 PM
The license remains valid even if the product is not sold in the US. For example, the live shingles vaccine (Zostavax) is still licensed but Merck does not sell it in the US. The left the US market after ACIP made a preferential recommendation for the recombinant shingles vaccine (Shingrix).
There are other monovalent measles vaccines but I think only Attenuvax is licensed in the US. The path to licensure is slow and uncertain.
October 10, 2025 at 2:57 AM
There are other monovalent measles vaccines but I think only Attenuvax is licensed in the US. The path to licensure is slow and uncertain.